GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2007

Vastox Signs Two Drug Discovery Deals

  • VASTox signed two long-term chemical genomics deals with a combined value of Euro $1 million. In the first transaction, VASTox entered into a drug discovery and toxicology screening collaboration with Rottapharm. It is worth up to Euro 365,000 over 12 months, which includes an upfront payment and research funding milestones.

    Under the terms of this partnership, the companies will generate a screening model for osteoarthritis to test potential drug candidates. The firms believe that this will accelerate Rottapharm’s discovery program. In addition, VASTox will provide predictive safety and toxicology testing with its vivo™ technology platform.

    The second agreement is with an unnamed European biotechnology company and will use VASTox’ medicinal chemistry expertise and experience in research to support one of the client’s drug discovery program. VASTox will receive up to Euro 635,000 over 10 months.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »